[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abivax Sa ADR (ABVX)

Abivax Sa ADR (ABVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,574,310
  • Shares Outstanding, K 79,770
  • Annual Sales, $ 0 K
  • Annual Income, $ -380,270 K
  • EBIT $ -294 M
  • EBITDA $ -293 M
  • 60-Month Beta 0.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 21.01

Options Overview Details

View History
  • Implied Volatility 65.78% (-7.29%)
  • Historical Volatility 213.75%
  • IV Percentile 15%
  • IV Rank 16.22%
  • IV High 171.25% on 05/22/26
  • IV Low 45.36% on 10/22/25
  • Expected Move (DTE 8) 10.92 (7.57%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 21,749
  • Volume Avg (30-Day) 24,587
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 223,591
  • Open Int (30-Day) 167,901
  • Expected Range 133.30 to 155.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.75
  • Number of Estimates 2
  • High Estimate $-0.69
  • Low Estimate $-0.81
  • Prior Year $-0.86
  • Growth Rate Est. (year over year) +12.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.79 +93.27%
on 06/24/26
146.68 -1.46%
on 07/02/26
+72.04 (+99.37%)
since 06/02/26
3-Month
69.81 +107.05%
on 06/02/26
146.68 -1.46%
on 07/02/26
+26.17 (+22.11%)
since 04/02/26
52-Week
7.64 +1,790.71%
on 07/03/25
148.83 -2.88%
on 12/24/25
+136.79 (+1,762.69%)
since 07/02/25

Most Recent Stories

More News
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm

Los Angeles , June 11, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A....

ABVX : 143.26 (+8.07%)
ABVX DEADLINE: The Gross Law Firm Reminds ABIVAX Societe Anonyme Investors of Upcoming Securities Class Action Deadline

NEW YORK , June 9, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ABIVAX Societe Anonyme (NASDAQ: ABVX).

ABVX : 143.26 (+8.07%)
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 8, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A....

ABVX : 143.26 (+8.07%)
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against ABIVAX Societe Anonyme (ABVX)

New York, New York--(Newsfile Corp. - June 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ABIVAX Societe Anonyme ("ABIVAX Societe Anonyme") (NASDAQ: ABVX) concerning...

ABVX : 143.26 (+8.07%)
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A. (“Abivax” or “the Company”) (NASDAQ:...

ABVX : 143.26 (+8.07%)
Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)

Jefferies downgraded Abivax from Buy to Hold and slashed its price target by nearly 44% after rare cancer cases emerged in the company's Phase 3 ulcerative colitis trial -- shares more than 40% of their...

ABVX : 143.26 (+8.07%)
Abivax SA Sponsored ADR (ABVX) Receives a Rating Update from a Top Analyst

In a report released on October 6, Thomas Smith from Leerink Partners reiterated a Buy rating on Abivax SA Sponsored ADR. The company’s shares closed yesterday at $87.01.Elevate Your Investing Strategy:...

ABVX : 143.26 (+8.07%)
Kepler Capital Sticks to Their Buy Rating for Abivax SA (0RA9)

Kepler Capital analyst Justine Telliez maintained a Buy rating on Abivax SA on October 6 and set a price target of €70.00. The company’s shares closed yesterday at €73.50.Elevate Your Investing Strategy:...

ABVX : 143.26 (+8.07%)
Why This French Biotech Stock Just Soared 586% in One Day

Shares of Abivax SA (NASDAQ: ABVX) went parabolic on Wednesday, skyrocketing 586% to close at $68.60 after the French biotech firm announced overwhelmingly positive Phase 3 data for its lead drug candidate,...

NDAQ : 84.33 (+1.93%)
PTN : 11.26 (+9.00%)
ABVX : 143.26 (+8.07%)
PTNT : 26.01 (-1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Abivax SA is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax SA is based in PARIS, FRANCE.

See More

Key Turning Points

3rd Resistance Point 144.81
2nd Resistance Point 142.08
1st Resistance Point 137.32
Last Price 143.26
1st Support Level 129.83
2nd Support Level 127.10
3rd Support Level 122.34

See More

52-Week High 148.83
Last Price 143.26
Fibonacci 61.8% 94.90
Fibonacci 50% 78.24
Fibonacci 38.2% 61.58
52-Week Low 7.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.